Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Novartis Pharmaceuticals
With
Subjects were stratified by * Prior (neo) adjuvant HER2/neu targeted therapy (yes, no) * Prior (neo) adjuvant taxane chemotherapy (yes, no) * Planned taxane treatment (once weekly paclitaxel versus docetaxel once every 3 weeks) * Liver metastasis (yes, no) Subjects were randomized 1:1 to the following treatments to a planned sample size of approximately 600 subjects (to achieve 536 centrally confirmed HER2 positive subjects): * Taxane based chemotherapy plus lapatinib for 24 weeks followed by single agent lapatinib * Taxane based chemotherapy plus trastuzumab for 24 weeks followed by single agent trastuzumab The choice of taxane (once weekly paclitaxel versus docetaxel once every 3 weeks) was at the discretion of the treating physician and was specified at the time of subject randomization. A protocol-specified interim analysis was conducted on 27-Apr-2012, following which the participants in the Lapatinib plus taxane based chemotherapy arm could cross over to Taxane based chemotherapy plus Trastuzumab.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted